1. Home
  2. KIDS vs OMER Comparison

KIDS vs OMER Comparison

Compare KIDS & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OrthoPediatrics Corp.

KIDS

OrthoPediatrics Corp.

HOLD

Current Price

$20.87

Market Cap

512.4M

Sector

Health Care

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$12.51

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KIDS
OMER
Founded
2007
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
512.4M
844.6M
IPO Year
2016
2008

Fundamental Metrics

Financial Performance
Metric
KIDS
OMER
Price
$20.87
$12.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
5
Target Price
$24.67
$32.50
AVG Volume (30 Days)
131.8K
1.4M
Earning Date
04-30-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.62
Revenue
$98,049,000.00
$29,868,000.00
Revenue This Year
$14.07
N/A
Revenue Next Year
$11.85
$233.22
P/E Ratio
N/A
$19.10
Revenue Growth
37.95
N/A
52 Week Low
$14.42
$3.61
52 Week High
$22.80
$17.65

Technical Indicators

Market Signals
Indicator
KIDS
OMER
Relative Strength Index (RSI) 62.41 65.66
Support Level $15.66 $10.82
Resistance Level $21.40 $12.53
Average True Range (ATR) 1.06 0.66
MACD 0.06 0.28
Stochastic Oscillator 83.41 94.93

Price Performance

Historical Comparison
KIDS
OMER

About KIDS OrthoPediatrics Corp.

OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: